1. Home
  2. IMMX
  3. IMMX News

Latest Immix Biopharma Inc. (IMMX) News on November 25, 2025

We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully
IMMX

Simply Wall St.

a day ago

We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
IMMX

GlobeNewswire

13 days ago

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
IMMX

GlobeNewswire

22 days ago

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

Immix Biopharma, Inc. (NASDAQ:IMMX) surges 10%; individual investors who own 56% shares profited along with insiders
IMMX

Simply Wall St.

a month ago

Immix Biopharma, Inc. (NASDAQ:IMMX) surges 10%; individual investors who own 56% shares profited along with insiders

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
IMMX

GlobeNewswire

a month ago

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
IMMX

GlobeNewswire

2 months ago

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?
IMMX

Zacks

6 months ago

Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?

Immix Biopharma Attends FDA CEO Forum in Washington DC
IMMX

GlobeNewswire

6 months ago

Immix Biopharma Attends FDA CEO Forum in Washington DC

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
IMMX

Insider Monkey

6 months ago

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

IMMX

MT Newswires

6 months ago

Immix Biopharma's NXC-201 Trial Meets Primary Endpoint in AL Amyloidosis

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
IMMX

GlobeNewswire

6 months ago

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
IMMX

GlobeNewswire

6 months ago

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
IMMX

GlobeNewswire

6 months ago

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
IMMX

GlobeNewswire

6 months ago

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

We're Keeping An Eye On Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate
IMMX

Simply Wall St.

6 months ago

We're Keeping An Eye On Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
IMMX

GlobeNewswire

7 months ago

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

IMMX

MT Newswires

9 months ago

Immix Biopharma Says FDA Grants Regenerative Medicine Advanced Therapy Designation to NXC-201 Cell Therapy

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
IMMX

GlobeNewswire

9 months ago

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Several Insiders Invested In Immix Biopharma Flagging Positive News
IMMX

Simply Wall St.

10 months ago

Several Insiders Invested In Immix Biopharma Flagging Positive News

IMMX

MT Newswires

a year ago

Immix Biopharma Says Patients Dosed in AL Amyloidosis Trial Safety Run-in Successfully Complete Safety Evaluation

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
IMMX

GlobeNewswire

a year ago

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

IMMX

MT Newswires

a year ago

Immix Biopharma Reports Initial Data from US Trial of NXC-201 CAR-T Therapy for AL Amyloidosis

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
IMMX

GlobeNewswire

a year ago

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
IMMX

GlobeNewswire

a year ago

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

IMMX

MT Newswires

a year ago

Immix Biopharma Gives Update on Clinical Data for Rare Disease Drug Candidate; Shares Lower

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
IMMX

GlobeNewswire

a year ago

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
IMMX

Simply Wall St.

a year ago

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
IMMX

GlobeNewswire

a year ago

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
IMMX

GlobeNewswire

a year ago

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
IMMX

GlobeNewswire

a year ago

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
IMMX

GlobeNewswire

a year ago

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 09/06/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 09/05/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 09/04/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 09/03/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/30/2024

Immix Biopharma Independent Director Acquires 2.6% More Stock
IMMX

Simply Wall St.

a year ago

Immix Biopharma Independent Director Acquires 2.6% More Stock

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/29/2024

IMMX

MT Newswires

a year ago

Sector Update: Health Care Stocks Ease in Afternoon Trading

IMMX

MT Newswires

a year ago

Immix Biopharma Expands US Nexicart-2 Trial for AL Amyloidosis With 3 Clinical Sites

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
IMMX

GlobeNewswire

a year ago

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/28/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/27/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/26/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/23/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/22/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/21/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/20/2024

What Makes Immix Biopharma (IMMX) a New Buy Stock
IMMX

Zacks

a year ago

What Makes Immix Biopharma (IMMX) a New Buy Stock

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/14/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/13/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/12/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/09/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/08/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/07/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/06/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/06/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/05/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/02/2024

IMMX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 08/01/2024

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
IMMX

GlobeNewswire

a year ago

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

IMMX

MT Newswires

a year ago

Immix Biopharma Doses First Patient in US AL Amyloidosis Trial With NXC-201

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
IMMX

GlobeNewswire

a year ago

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
IMMX

Simply Wall St.

a year ago

Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
IMMX

GlobeNewswire

a year ago

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
IMMX

GlobeNewswire

a year ago

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

Immix Biopharma Insiders Placed Bullish Bets Worth US$625.7k
IMMX

Simply Wall St.

2 years ago

Immix Biopharma Insiders Placed Bullish Bets Worth US$625.7k

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
IMMX

GlobeNewswire

2 years ago

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

IMMX

MT Newswires

2 years ago

Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
IMMX

GlobeNewswire

2 years ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

Immix Biopharma on Track to Dose NXC-201 Patients in United States
IMMX

GlobeNewswire

2 years ago

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
IMMX

GlobeNewswire

2 years ago

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
IMMX

GlobeNewswire

2 years ago

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
IMMX

GlobeNewswire

2 years ago

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Immix Biopharma 12 Month Review Progress Update
IMMX

GlobeNewswire

2 years ago

Immix Biopharma 12 Month Review Progress Update

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
IMMX

GlobeNewswire

2 years ago

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
IMMX

GlobeNewswire

2 years ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
IMMX

GlobeNewswire

2 years ago

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

Immix Biopharma Announces Proposed Public Offering of Common Stock
IMMX

GlobeNewswire

2 years ago

Immix Biopharma Announces Proposed Public Offering of Common Stock

IMMX

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 02/02/2024

Relmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 Shares
IMMX

GuruFocus.com

2 years ago

Relmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 Shares

Innovid to Release Fourth Quarter & Full Year 2023 Financial Results on February 27th
IMMX

Business Wire

2 years ago

Innovid to Release Fourth Quarter & Full Year 2023 Financial Results on February 27th

Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference
IMMX

GlobeNewswire

2 years ago

Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference

Bears are Losing Control Over Bank7 (BSVN), Here's Why It's a 'Buy' Now
IMMX

Zacks

2 years ago

Bears are Losing Control Over Bank7 (BSVN), Here's Why It's a 'Buy' Now

Riverview Bancorp (RVSB) Q3 Earnings and Revenues Miss Estimates
IMMX

Zacks

2 years ago

Riverview Bancorp (RVSB) Q3 Earnings and Revenues Miss Estimates

Fidelity D & D Bancorp Inc (FDBC) Reports Decline in Annual Net Income Amid Balance Sheet ...
IMMX

GuruFocus.com

2 years ago

Fidelity D & D Bancorp Inc (FDBC) Reports Decline in Annual Net Income Amid Balance Sheet ...

7 EV Stocks to Turn $100,000 Into $1 Million: January 2024
IMMX

InvestorPlace

2 years ago

7 EV Stocks to Turn $100,000 Into $1 Million: January 2024

One Reservoir Media Insider Raised Stake By 37% In Previous Year
IMMX

Simply Wall St.

2 years ago

One Reservoir Media Insider Raised Stake By 37% In Previous Year

Why QuickLogic (QUIK) Outpaced the Stock Market Today
IMMX

Zacks

2 years ago

Why QuickLogic (QUIK) Outpaced the Stock Market Today

Shareholders in America's Car-Mart (NASDAQ:CRMT) are in the red if they invested three years ago
IMMX

Simply Wall St.

2 years ago

Shareholders in America's Car-Mart (NASDAQ:CRMT) are in the red if they invested three years ago

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
IMMX

GlobeNewswire

2 years ago

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

IMMX

Associated Press Finance

2 years ago

FVCBankcorp: Q4 Earnings Snapshot

FVCBankcorp, Inc. Announces 2023 Earnings
IMMX

Business Wire

2 years ago

FVCBankcorp, Inc. Announces 2023 Earnings

7 Speculative Stocks to Double Your Money THIS Year
IMMX

InvestorPlace

2 years ago

7 Speculative Stocks to Double Your Money THIS Year

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET
IMMX

GlobeNewswire

2 years ago

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

IMMX

GlobeNewswire

2 years ago

Abpro Announces Filing of Registration Statement on Form S-4 in Connection with Business Combination Agreement with Atlantic Coastal Acquisition Corp. II

IMMX

GlobeNewswire

2 years ago

QuantaSing Announces Appointment of New Independent Director

Both retail investors who control a good portion of Absci Corporation (NASDAQ:ABSI) along with institutions must be dismayed after last week's 15% decrease
IMMX

Simply Wall St.

2 years ago

Both retail investors who control a good portion of Absci Corporation (NASDAQ:ABSI) along with institutions must be dismayed after last week's 15% decrease

Piedmont Lithium Sells Portion of Atlantic Shares to Assore
IMMX

Business Wire

2 years ago

Piedmont Lithium Sells Portion of Atlantic Shares to Assore

With 35% stake, Pegasus Digital Mobility Acquisition Corp. (NYSE:PGSS) seems to have captured institutional investors' interest
IMMX

Simply Wall St.

2 years ago

With 35% stake, Pegasus Digital Mobility Acquisition Corp. (NYSE:PGSS) seems to have captured institutional investors' interest

Share on Social Networks: